IQGAP1 interacts with MYL9 and acts on the ERK1/2 pathway to regulate cancer-associated fibroblasts (CAFs), which secrete CCL2 and TGF-β1, thereby influencing the tumor microenvironment and patient outcomes (80). Here, CCL2 is linked to neoplasm.